Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Characterization of human allogenenic double negative T cells as a novel immunotherapy against acute myeloid leukemia
FY 2014-15
Summary
Acute myeloid leukemia (AML) is the most common form of adult acute leukemia. AML is associated with low long-term survival rate, where less than 30% of younger patients and 5% of elderly patients survive 5 years or longer after diagnosis. Chemotherapy is the current conventional treatment for AML patients, which can reduce the level of AML to an undetectable level in more than 70% of treated patients. However, AML re-occurs in most of these patients due to a population of cancer cells that is resistant to the initial treatment. The goal of this project is to develop a novel therapy that utilizes our immune cell called double negative T cell (DNT) to overcome the limitations associated with the conventional chemotherapy for AML patient. Our lab has developed a method to expand DNT cells to a number needed for clinical treatments and demonstrated that DNT cells can effectively attack chemotherapy resistant AML, but do not target normal cells. Furthermore, greater reduction in AML frequency was observed with DNT cell and chemo-drug combined treatment than chemotherapy alone in an AML animal model. In this project, our knowledge on DNT cells will be further expanded by validating the safety of DNT therapy in an animal model. Also, the activity of DNT cells against the recurrent AML initiating population, and the mechanism of DNT-mediated selective recognition and targeting of cancerous cells and the DNT-chemotherapy combined treatment will be determined. Based on our previous results, we predict that DNT therapy is safe and effective to use against the recurrent AML initiating cells in vivo, and it works in synergistically with chemotherapy. Successful development of DNT therapy will provide a new approach to treat chemotherapy non-responding and recurrent AML patients and lower the rate of recurrent AML in newly diagnosed AML patients, and ultimately increase the overall survival rate in AML patients.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
318246
Name
Lee Jong Bok
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Characterization of human allogenenic double negative T cells as a novel immunotherapy against acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Cancer; Cancer Stem Cell; Cellular Therapy; Immunotherapy; T Cell
Abstract
Acute myeloid leukemia (AML) is the most common form of adult acute leukemia. AML is associated with low long-term survival rate, where less than 30% of younger patients and 5% of elderly patients survive 5 years or longer after diagnosis. Chemotherapy is the current conventional treatment for AML patients, which can reduce the level of AML to an undetectable level in more than 70% of treated patients. However, AML re-occurs in most of these patients due to a population of cancer cells that is resistant to the initial treatment. The goal of this project is to develop a novel therapy that utilizes our immune cell called double negative T cell (DNT) to overcome the limitations associated with the conventional chemotherapy for AML patient. Our lab has developed a method to expand DNT cells to a number needed for clinical treatments and demonstrated that DNT cells can effectively attack chemotherapy resistant AML, but do not target normal cells. Furthermore, greater reduction in AML frequency was observed with DNT cell and chemo-drug combined treatment than chemotherapy alone in an AML animal model. In this project, our knowledge on DNT cells will be further expanded by validating the safety of DNT therapy in an animal model. Also, the activity of DNT cells against the recurrent AML initiating population, and the mechanism of DNT-mediated selective recognition and targeting of cancerous cells and the DNT-chemotherapy combined treatment will be determined. Based on our previous results, we predict that DNT therapy is safe and effective to use against the recurrent AML initiating cells in vivo, and it works in synergistically with chemotherapy. Successful development of DNT therapy will provide a new approach to treat chemotherapy non-responding and recurrent AML patients and lower the rate of recurrent AML in newly diagnosed AML patients, and ultimately increase the overall survival rate in AML patients.
Competitiondate
201411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lee, Jong Bok
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~